Medicare Enrolled
Susan Mathew, M .D.
Optician · Sugar Land, TX
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Mathew from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Mathew?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Mathew
Susan Mathew is an optician specialist in Sugar Land, TX, with 15 years of NPI registration. Based on federal Medicare data, Mathew performed 114,032 Medicare services in 2023. These records do not provide a deduplicated patient total.
Between the years covered by Open Payments, Mathew received a total of $55,262 from 42 pharmaceutical and/or device companies across 978 payment records. A record can group multiple payments. These transfers are publicly reported through CMS Open Payments. Disclosure alone does not establish their effect on care. A reliable breakdown by payment category is not available in this snapshot. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Mathew is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 15 years of NPI registration
▲ Top 1% volume in TX
$55,262 industry payments
Medicare Practice Summary — 2023
Medicare Utilization ↗114,032
Medicare services
Top 1% in TX for optician
Not available
Unique patients (not deduplicated)
$5
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Certolizumab injection (Cimzia) An injection of certolizumab pegol administered under the direct supervision of a physician. |
98,800 | $4 | $30 |
| Golimumab infusion (Simponi Aria) Administration of golimumab medication directly into a vein. This code specifies the dosage amount of 1 milligram for intravenous delivery. |
12,883 | $10 | $76 |
| Non-hormonal chemotherapy injection This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue. |
494 | $55 | $218 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
440 | $88 | $157 |
| Steroid injection (triamcinolone) A 10 mg injection of triamcinolone acetonide, a corticosteroid medication. This code specifies the drug and dosage administered. |
250 | $1 | $30 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
182 | $8 | $11 |
| Sed rate test (inflammation marker) This automated test measures how quickly red blood cells settle in a tube to detect inflammation in the body. |
174 | $3 | $21 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
168 | $8 | $26 |
| C-reactive protein test (inflammation marker) A blood test that measures the level of C-reactive protein to detect the presence of infection or inflammation in the body. |
157 | $5 | $29 |
| Comprehensive metabolic blood panel A blood test that measures a group of chemicals, including glucose, electrolytes, and kidney and liver function markers. |
151 | $10 | $50 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
85 | $89 | $600 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
52 | $10 | $70 |
| New patient office visit, complex (60-74 min) | 49 | $141 | $300 |
| Joint injection, major joint Removal of fluid from a large joint and/or injection of medication into the joint space. |
41 | $48 | $188 |
| Uric acid level test A blood test that measures the level of uric acid in your body. Uric acid is a waste product formed when the body breaks down purines. |
28 | $4 | $21 |
| X-ray of hand, minimum of 3 views An X-ray imaging test of the hand that captures at least three different angles to visualize the bones and joints. |
21 | $28 | $105 |
| Cardiac enzyme level (CK-MB) test A blood test that measures the total level of creatine kinase, specifically the cardiac enzyme fraction, to help evaluate heart muscle damage. |
21 | $6 | $26 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
19 | $130 | $208 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
17 | $61 | $112 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. These counts do not measure clinical quality or years of experience.
11.4% high complexity
87.4% medium
1.3% routine
Industry Payment Transparency
Open Payments through 2024 ↗$55,262
Total received (2018-2024)
Avg $7,895/year across 7 years
Top 5% in TX for optician
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
42
Companies
978
Payment records
Payments are publicly reported; disclosure does not establish legality · Not evidence of wrongdoing · How to interpret →
Payment categories are unavailable while the source breakdown is being rebuilt. Company and year totals do not identify how much belongs to each category.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$9,708
2023
$3,488
2022
$5,033
2021
$5,317
2020
$7,917
2019
$20,858
2018
$2,942
Payments by company (2024)
UCB, Inc.
$4,576
Janssen Biotech, Inc.
$2,421
ABBVIE INC.
$838
Amgen Inc.
$461
ANI Pharmaceuticals, Inc.
$255
PFIZER INC.
$248
Lilly USA, LLC
$161
Novartis Pharmaceuticals Corporation
$148
AstraZeneca Pharmaceuticals LP
$117
GlaxoSmithKline, LLC.
$112
Nevro Corp.
$99
GENZYME CORPORATION
$95
Alexion Pharmaceuticals, Inc.
$58
E.R. Squibb & Sons, L.L.C.
$30
Radius Health, Inc.
$23
Boehringer Ingelheim Pharmaceuticals, Inc.
$20
Aurinia Pharma U.S., Inc.
$17
Bioventus LLC
$15
Mallinckrodt Hospital Products Inc.
$14
Top 3 companies account for 80.7% of 2024 payments
All-time payments by company (2018-2024) ›
Mallinckrodt Enterprises LLC
$17,499
Mallinckrodt Hospital Products Inc.
$12,361
UCB, Inc.
$5,788
Janssen Biotech, Inc.
$3,045
ABBVIE INC.
$2,717
Amgen Inc.
$2,205
PFIZER INC.
$1,386
Horizon Therapeutics plc
$1,352
Celgene Corporation
$1,328
Novartis Pharmaceuticals Corporation
$1,296
Lilly USA, LLC
$929
GlaxoSmithKline, LLC.
$635
AstraZeneca Pharmaceuticals LP
$460
AbbVie, Inc.
$448
GENZYME CORPORATION
$419
Nevro Corp.
$391
Radius Health, Inc.
$379
E.R. Squibb & Sons, L.L.C.
$359
AbbVie Inc.
$344
Aurinia Pharma U.S., Inc.
$338
ANI Pharmaceuticals, Inc.
$255
Alexion Pharmaceuticals, Inc.
$154
Mallinckrodt LLC
$131
Johnson & Johnson Health Care Systems Inc.
$129
MEDEXUS PHARMA, INC.
$128
Teva Pharmaceuticals USA, Inc.
$120
Horizon Pharma plc
$113
Genentech USA, Inc.
$93
Boehringer Ingelheim Pharmaceuticals, Inc.
$79
SANOFI-AVENTIS U.S. LLC
$77
Kiniksa Pharmaceuticals, Ltd.
$52
Sandoz Inc.
$45
Gilead Sciences, Inc.
$43
Takeda Pharmaceuticals U.S.A., Inc.
$26
Ultragenyx Pharmaceutical Inc.
$25
Medtronic, Inc.
$20
Sobi, Inc
$20
Antares Pharma, Inc.
$17
Celltrion USA Inc.
$16
Bioventus LLC
$15
IBSA Pharma Inc.
$14
Janssen Pharmaceuticals, Inc
$13
Top 3 companies account for 64.5% of all-time payments
Associated products mentioned in payments ›
ACTHAR · AJOVY · AMJEVITA · Actemra · Arcalyst · BENLYSTA · Bimzelx · COLOGUARD · COSENTYX · CYLTEZO · Cimzia · Crysvita · DUEXIS · DUROLANE · EUCRISA · EVENITY · EVUSHELD · Enbrel · FORTEO · HUMIRA · HYRIMOZ · Humira · ILARIS · INTELLIS ADAPTIVESTIM · JARDIANCE · KEVZARA · KRYSTEXXA · Kineret · LUPKYNIS · LYRICA · ORENCIA · Otezla · Otrexup · PENNSAID · PURIFIED CORTROPHIN GEL · Prolia · QULIPTA · RAYOS · REMICADE · RHEUMATOID ARTHRITIS DISEASE · RINVOQ · Rasuvo · Rinvoq · Rituxan · SAPHNELO · SIMPONI ARIA · SKYRIZI · STELARA · STRENSIQ · Senza · Senza Spinal Cord Stimulation System · Strensiq · TALTZ · TAVNEOS · TEFLARO · TRELEGY ELLIPTA · TREMFYA · Tavneos · Tirosint · Trintellix · Tymlos · UBRELVY · Uloric · VIMOVO · VRAYLAR · XARELTO · XELJANZ · YUFLYMA
Should you be concerned? Industry payments are disclosed through CMS Open Payments. Disclosure alone does not establish their purpose, legality, or effect on care. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Geographic Context
Opticians in nearby ZIP areas
440
County median income
$113,409
Nearest hospital to ZIP centroid (approximate)
ST LUKE'S SUGAR LAND HOSPITAL
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | NPPES snapshot; verify current record |
| Medicare Enrollment | ✓ PECOS | PECOS snapshot |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not included | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Mathew is a mixed practice specialist, with above-average Medicare volume (top 1% in TX), with 15 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Mathew experienced with certolizumab injection (cimzia)?
Based on Medicare claims data, Mathew performed 98,800 certolizumab injection (cimzia) services. These records cover Medicare fee-for-service activity, including eligible younger beneficiaries; they do not measure total practice volume or clinical quality.
Does Mathew receive payments from pharmaceutical companies?
Yes. Mathew received a total of $55,262 from 42 companies across 978 payment records. A record can group multiple payments. These transfers are publicly disclosed through CMS Open Payments. Disclosure alone does not establish their legality or effect on care. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Mathew's costs compare to other opticians in Sugar Land?
Mathew's average Medicare payment per service is $5. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Mathew) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating the presence of registry, enrollment, activity or payment records, not verified experience or clinical quality. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Source publication dates and the snapshots loaded on this site can differ. Rebuilding a page does not refresh its source records. Check the Medicare reporting year and the payment interval shown above; consult the linked official sources for newer releases and current registry details. See our data freshness policy →
Explore related providers
Same specialty & city
Opticians in Sugar Land
Browse opticians in Sugar Land ranked by procedure volume and transparency data.
Highest volume
Top Opticians in TX
Opticians ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Opticians in TX
Which TX opticians receive the most from drug and device companies.
By company
Mallinckrodt Enterprises LLC Payments to Doctors
See all physicians who received payments from Mallinckrodt Enterprises LLC.
By company
Mallinckrodt Hospital Products Inc. Payments to Doctors
See all physicians who received payments from Mallinckrodt Hospital Products Inc.
By company
UCB, Inc. Payments to Doctors
See all physicians who received payments from UCB, Inc.
About this page
This page combines public CMS records with calculated summaries and explanatory procedure labels. These transformations are not verbatim federal records. Sources: NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology